H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion
H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.
How this was made
The 30-second read
Why it matters
The analyst’s PT reduction is linked to updated trial design and ongoing development milestones, while the disclosed equity offering and warrant exercises introduce dilution and funding overhang risk.
Market read
Traders get a fresh valuation signal (PT cut) tied to updated clinical trial structure, alongside explicit dilution-related financing details.
What to watch
The article also notes a large public offering and warrant exercises, which can drive near-term price pressure independent of trial outcomes, potentially exaggerating the immediate reaction to the PT change.
Background
Shattuck Labs is advancing Crohn’s disease candidate SL-325 in a Phase 2b trial and progressing a separate DR3 x IL-23 bispecific program (SL-846).
Ticker impact
H.C. Wainwright cut Shattuck Labs’ price target to $14 from $18 after the company expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients.
Near-term downside bias from the PT cut and dilution overhang, partially offset by the stated trial readiness and continued development progress.
The article’s actionable catalyst is the analyst PT reduction following Q2 results and trial protocol expansion, while the offering and warrant exercises add financing/dilution risk that can cap upside.
Market effects
Biotech sentiment may soften for clinical-stage immunology names when PT cuts coincide with dilutive capital raises.
Limited, primarily affects US small-cap biotech risk appetite.
Low, no cross-border regulatory or partnership catalyst described.
Counterpoint
The PT cut may be more about valuation than science; the trial remains on track for Q3 2026 initiation and provides clearer dose-ranging structure.
Key entities
- companyShattuck Labs
NASDAQ-listed biotech whose RECEPTIVE-CD1 trial design was expanded and whose financing activity was described.
- analyst_firmH.C. Wainwright
Issued the price target cut to $14 from $18 while maintaining a Buy rating.
- analyst_firmJPMorgan
Reiterated Overweight with a $10 price target, citing the anti-DR3 antibody program.
